BioTelemetry Inc

Most Recent

  • uploads///BEAT PE MC
    Healthcare

    Analyzing BEAT, SUPN, ADBE And RHT Stocks

    Growth stock analysis   BioTelemetry BioTelemetry’s (BEAT) net income has declined at a 3-year and 5-year average of 17% and 5.9% respectively. The company’s negative pre-tax margin changed from 5.5% in 2013 to 3.6% in 2017. The stock prices have beaten the diagnostics & research industry and S&P 500 between 2013 and 2017. The market […]

    By Amanda Lawrence
  • uploads///proj pe ratio
    Consumer

    Total Returns and Sector Exposure for Growth Indexes—Continued

    The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively.

    By Amanda Lawrence
  • uploads///GROWTH INDEX EXPO TO IT
    Consumer

    Total Returns and Sector Exposure for Growth Indexes

    If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT).

    By Amanda Lawrence
  • uploads///family _
    Company & Industry Overviews

    What Analysts Recommend for Amedisys and Peers in March 2018

    Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///ambulance __
    Company & Industry Overviews

    Analyst Ratings for BioTelemetry and Its Peers in March 2018

    Of the seven analysts covering BioTelemetry in March 2018, two have given it a “strong buy” rating, and five have given it a “buy.”

    By Kenneth Smith
  • uploads///BEAT
    Company & Industry Overviews

    A Look at BioTelemetry’s Financial Performance

    In fiscal 2017, BioTelemetry (BEAT) generated total revenues of $286.7 million.

    By Kenneth Smith
  • uploads///BEAT
    Company & Industry Overviews

    Understanding BioTelemetry’s Business Strategy

    BioTelemetry’s (BEAT) business strategy is to solidify its position as a leading provider of outpatient cardiac monitoring services.

    By Kenneth Smith
  • uploads///BEAT
    Company & Industry Overviews

    Exploring BioTelemetry’s Segments

    BioTelemetry’s healthcare segment contributed 81% of the company’s total revenues in fiscal 2017.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.